# Phase 1/2 Diabetes Mellitus trials recruiting: 33 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 33 trials in phase 1/2 for Diabetes Mellitus that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Diabetes Mellitus trials: 33 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/diabetes-mellitus

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 33
- Recruiting or not yet: 33
- Read on: November 19, 2026

## Trials

The 25 newest of 33, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07940803 | A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 Diabetes | Novo Nordisk A/S | Phase 1/2 | Not yet recruiting | Overweight, Obesity, Type 2 Diabetes Mellitus | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940803) |
| November 9, 2026 | NCT07925801 | Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol Secretion | The University of Texas Health Science Center at San Antonio | Phase 1/2 | Not yet recruiting | Type 2 Diabetes, Hypercortisolism | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925801) |
| October 28, 2026 | NCT07901595 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2... | Paulex Bio Inc. | Phase 1/2 | Not yet recruiting | Healthy Volunteers and Diabetes Participants | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901595) |
| October 5, 2026 | NCT07857135 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Advanced/Metastatic Solid Tumors | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857135) |
| September 21, 2026 | NCT07831798 | VV-14300 for the Treatment of Type 1 Diabetes | Kriya Therapeutics, Inc. | Phase 1/2 | Recruiting | Type 1 Diabetes Mellitus | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831798) |
| September 21, 2026 | NCT07829302 | VV-14299 and VV-14300 for the Treatment of Type 1 Diabetes | Kriya Therapeutics, Inc. | Phase 1/2 | Recruiting | Type 1 Diabetes Mellitus | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829302) |
| July 31, 2026 | NCT07738341 | GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) | Eddingpharm (Zhuhai) Co., Ltd. | Phase 1/2 | Recruiting | Breast Cancer (Locally Advanced or Metastatic) | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738341) |
| July 14, 2026 | NCT07702890 | A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and... | Gubra A/S | Phase 1/2 | Recruiting | Obesity, Type 2 Diabetes | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07702890) |
| July 9, 2026 | NCT07693036 | hUC-MSC-Exosomes for T2DM - Safety & Efficacy | Peking University First Hospital | Phase 1/2 | Recruiting | Type 2 Diabetes Mellitus (T2DM) | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07693036) |
| May 12, 2026 | NCT07581197 | Study of the Safety and Efficacy of Pancreatic Endocrine Cells in Adult Patients With Type 1 Diabetes | Seraxis | Phase 1/2 | Not yet recruiting | Diabete Mellitus, Diabete Type 1 | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581197) |
| May 4, 2026 | NCT07563699 | Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus | Mapi Pharma Ltd. | Phase 1/2 | Recruiting | Diabete Type 2 | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07563699) |
| March 27, 2026 | NCT07495956 | cfMSC Therapy for Diabetes | Shenzhen Geno-Immune Medical Institute | Phase 1/2 | Not yet recruiting | Type II Diabetes Mellitus | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07495956) |
| March 16, 2026 | NCT07472907 | A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have... | Cilcare SAS | Phase 1/2 | Not yet recruiting | Cochlear Synaptopathy | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472907) |
| January 28, 2026 | NCT07374328 | Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus | Second Affiliated Hospital of Guangzhou Medical University | Phase 1/2 | Recruiting | Type 2 Diabetes | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07374328) |
| December 24, 2025 | NCT07300982 | Studies of Insulin and Glucagon Action in the Liver | Duke University | Phase 1/2 | Not yet recruiting | Diabetes (DM) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07300982) |
| September 30, 2025 | NCT07199946 | A Phase I/II Trial to Preserve Residual Insulin Secretion in Children With Recent Onset Type 1 Diabetes by Giving Verapamil | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Type 1 Diabetes | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07199946) |
| September 11, 2025 | NCT07167693 | Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07167693) |
| August 17, 2025 | NCT07126873 | A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes | EndoCell Therapeutics, Inc. | Phase 1/2 | Recruiting | Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07126873) |
| July 11, 2025 | NCT07061574 | A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes | City of Hope Medical Center | Phase 1/2 | Recruiting | Type 1 Diabetes, New Onset | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07061574) |
| April 22, 2025 | NCT06938334 | A First-in-human Clinical Trial Using a Gene Therapy With Patient's Own Stem Cells to Treat Early Type 1 Diabetes | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Diabetes, Type I | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06938334) |
| April 22, 2025 | NCT06937203 | A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Arrowhead Pharmaceuticals | Phase 1/2 | Recruiting | Obesity, Diabetes Mellitus, Type 2 | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06937203) |
| January 20, 2025 | NCT06783309 | CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | COUR Pharmaceutical Development Company, Inc. | Phase 1/2 | Recruiting | Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes... | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06783309) |
| November 25, 2024 | NCT06703788 | Integrated Traditional Chinese Medicine Day Care Program for Metabolic Syndrome | Chang Gung Memorial Hospital | Phase 1/2 | Recruiting | Obesity, Metabolic Syndrome, Dyslipidemias, Diabetes Mellitus | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06703788) |
| August 28, 2024 | NCT06575426 | A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus | Otsuka Pharmaceutical Factory, Inc. | Phase 1/2 | Recruiting | Diabetes Mellitus, Type 1, Hypoglycemia, Islet Cell Transplantation, Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D... | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06575426) |
| July 29, 2024 | NCT06524960 | Denosumab for Type 1 Diabetes | City of Hope Medical Center | Phase 1/2 | Recruiting | Type 1 Diabetes | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06524960) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| City of Hope Medical Center | 3 |
| Shenzhen Geno-Immune Medical Institute | 2 |
| Kriya Therapeutics, Inc. | 2 |
| Seraxis | 1 |
| Cilcare SAS | 1 |
| COUR Pharmaceutical Development Company, Inc. | 1 |
| Duke University | 1 |
| Biolingus | 1 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 1 |
| Chang Gung Memorial Hospital | 1 |
| EndoCell Therapeutics, Inc. | 1 |
| Second Affiliated Hospital of Guangzhou Medical University | 1 |
| GI Innovation, Inc. | 1 |
| Aulos Bioscience, Inc. | 1 |
| [Arrowhead Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/arrowhead-pharmaceuticals) | 1 |
| Peking University First Hospital | 1 |
| The University of Texas Health Science Center at San Antonio | 1 |
| Creative Medical Technology Holdings Inc | 1 |
| Paulex Bio Inc. | 1 |
| Mapi Pharma Ltd. | 1 |
| Otsuka Pharmaceutical Factory, Inc. | 1 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 1 |
| Eddingpharm (Zhuhai) Co., Ltd. | 1 |
| Gubra A/S | 1 |
| University of Texas Southwestern Medical Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 14 |
| China | 6 |
| Australia | 3 |
| New Zealand | 2 |
| Italy | 1 |
| Hong Kong | 1 |
| Taiwan | 1 |
| Sweden | 1 |
| South Korea | 1 |
| Canada | 1 |
| Israel | 1 |
| Germany | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Livestock feed and supply stores in the United States](https://specstream.ai/data/businesses/livestock-feed-and-supply-stores/united-states)
- [Boat and ship manufacturers in the United States](https://specstream.ai/data/businesses/boat-and-ship-manufacturers/united-states)
- [Pizza restaurants in the United States](https://specstream.ai/data/businesses/pizza-restaurants/united-states)
- [Distribution companies in the United States](https://specstream.ai/data/businesses/distribution-companies/united-states)
- [Sports bars in the United States](https://specstream.ai/data/businesses/sports-bars/united-states)
- [Granite suppliers in the United States](https://specstream.ai/data/businesses/granite-suppliers/united-states)
